Aung(Latt)NaingMD

Clinical Trials

• Olanzapine in Patients With Advanced Cancer and Weight Loss Start of enrollment: 2006 Oct 01

  Completed

  Phase 1

• Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor Start of enrollment: 2007 Jun 01

  Completed

  Phase 1

• Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies Start of enrollment: 2006 Sep 13

  Completed

  Phase 1

• Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer Start of enrollment: 2008 May 01

  Completed

  Phase 1

• Phase I Study of TAS-106 in Combo With Carboplatin Start of enrollment: 2008 Jun 01

  Completed

  Phase 1

• Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials Start of enrollment: 2009 Jul 01

  Completed

• Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib Start of enrollment: 2012 Dec 01

  Withdrawn

  Phase 1

• The Role of the EKG in Anticancer Drug Development Start of enrollment: 2011 Jan 01

  Completed

• A Phase IIa, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sodium Stibogluconate in Combination With Interferon Alpha-2b for Patients With Advanced Malignancies Start of enrollment: 2006 Sep 01
• Temsirolimus in Combination With Metformin in Patients With Advanced Cancers Start of enrollment: 2012 Mar 26

  Active, not recruiting

  Phase 1

• Aerosolized Aldesleukin in Treating Patients With Lung Metastases Start of enrollment: 2012 Jun 28

  Active, not recruiting

  Phase 1

• Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Start of enrollment: 2013 Aug 13

  Completed

  Phase 1

• Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis Start of enrollment: 2014 Jul 10

  Terminated

  Phase 3

• BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01

  Completed

  Phase 1

• A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies Start of enrollment: 2013 Dec 19

  Completed

  Phase 1

• Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2014 Jun 18

  Completed

  Phase 1

• Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Start of enrollment: 2015 Nov 23

  Terminated

  Phase 1, Phase 2

• Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Start of enrollment: 2016 Aug 15

  Active, not recruiting

  Phase 2

• Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies Start of enrollment: 2017 Aug 02

  Active, not recruiting

  Phase 1, Phase 2

• Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies Start of enrollment: 2019 Oct 30

  Recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas Start of enrollment: 2020 Jun 05

  Completed

  Phase 1

• First in Human Study of M6223 Start of enrollment: 2020 Jul 10

  Completed

  Phase 1

  Roles: Principal Investigator

• Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies Start of enrollment: 2015 Jun 26

  Active, not recruiting

  Phase 1

  Roles: Contact, Principal Investigator

• Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors Start of enrollment: 2022 Apr 11

  Completed

  Phase 1

  Roles: Contact, Principal Investigator

• A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 Start of enrollment: 2023 Jul 21

  Recruiting

  Phase 1

  Roles: Contact

• A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors Start of enrollment: 2023 Jun 21

  Recruiting

  Phase 1, Phase 2

  Roles: Contact, Principal Investigator

• A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors Start of enrollment: 2022 Nov 29

  Recruiting

  Phase 1, Phase 2

  Roles: Principal Investigator

• A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7 Start of enrollment: 2024 Jan 22

  Recruiting

  Phase 1

  Roles: Contact

• Join now to see all